Incidence of Overactive Bladder in Benign Prostatic Hyperplasia and the Efficacy of Combination Therapy of Alpha Blocker with Tolterodine.
- Author:
Hyun Woo KIM
1
;
Sung Il SEO
;
Jun Sung KO
;
Ji Hak JUNG
;
Ji Youl LEE
Author Information
1. Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea. uroljy@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Benign prostatic hyperplasia;
Bladder;
Tolterodine
- MeSH:
Creatinine;
Humans;
Incidence*;
Prostate;
Prostatic Hyperplasia*;
Urinary Bladder;
Urinary Bladder, Overactive*;
Urodynamics;
Tolterodine Tartrate
- From:Korean Journal of Urology
2003;44(10):1006-1010
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The incidence of overactive bladder (OAB) and the efficacy of alpha blocker and tolterodine combination therapy were examined in patients with symptomatic benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: Between March 2001 and December 2001, 144 BPH patients were subdivided into those with BPH, or BPH with OAB, based on urodynamic studies. All patients were treated with alpha blockers for 3 months. Patients with no symptomatic improvement were treated with alpha blockers and tolterodine for 2 months. An increase in the International prostate symptom scores (IPSS) of more than 3 points after medication was considered an improvement, but if not, as a failure. RESULTS: Of the 144 patients, 76 (53%) had BPH and 68 (47%) had BPH with OAB. The patients with BPH and OAB were older (p<0.05), but no differences were observed in the serum creatinine, IPSS, prostate volume, maximum flow rate or post-void residual urine (PVR) between the 2 groups. After 3 months treatment with alpha blockers, 79% (60/76) of the BPH and 35% (24/68) of the BPH with OAB patients had improved (p<0.05). Of the patients showing no improvement, 38% (6/16) with BPH and 73% (32/44) with BPH and OAB showed improvement after the addition of tolterodine. CONCLUSIONS: The combination therapy was more effective than alpha blockers alone in the treatment of patients with coexisting BPH and OAB. We recommend identifying these patients with an initial urodynamic study, which allows for the appropriate management and identification of those patients that may benefit from a more invasive treatment.
